Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis

Table 1 Characteristics of randomized controlled trials included in the meta-analysis

Study no.	Authors	Region	Year	Trial phase	Primary endpoint	Interventions	Patients	Median OS (months)
1	Grothey et al. [25]	USA	2003	2	AEs	CapOx CapIRI	82 79	NA NA
2	Tournigand et al. [5]	France	2004	3	PFS	FOLFOX FOLFIRI	113 113	20.6 21.5
3	Kalofonos et al. [26]	Greece	2005	2	ORR	Weekly Ox + LV + 5-FU Weekly IRI + LV + 5-FU	148 147	17.4 17.6
4	Comella et al. [27]	Italy	2005	3	ORR	OXAFAFU IRIFAFU	140 133	18.9 15.6
5	Colucci et al. [6]	Italy	2005	3	ORR	FOLFOX FOLFIRI	182 178	15 14
6	Feliu et al. [28]	Spain	2005	2	ORR	Raltitrexed + Ox Raltitrexed + IRI	48 46	NA NA
7	Zheng et al. [29]	China	2006	2	ORR	FOLFOX7 FOLFIRI	30 30	NA NA
8	Bajetta et al. [30]	Italy	2007	2	AEs	TEGAFOX TEGAFIRI	73 68	19 20
9	Seymour et al. [31]	UK	2007	3	OS	OxFU IrFU	357 356	15.4 16.7
10	Rosati et al. [32]	Italy	2010	2	ORR	CapOx CapIRI	47 47	19.3 14
11	Ocvirk et al. [33]	Germany Austria	2010	2	PFS	FOLFOX6 + Cmab FOLFIRI + Cmab	77 74	17.4 18.9
12	Moosmann et al. [34]	Germany	2011	2	ORR	CapOx + Cmab CapIRI + Cmab	92 93	25.5 21.1
13	Schmiegel et al. [35]	Germany	2013	2	PFS	CapOx + BEV CapIRI + BEV	127 128	24.4 25.5
14	Folprecht et al. [36]	Germany Austria	2014	2	ORR	FOLFOX6 + Cmab FOLFIRI + Cmab	56 55	35.8 29
15	Yamazaki et al. [7]	Japan	2016	3	PFS	FOLFOX6 + BEV FOLFIRI + BEV	200 202	30.4 31.4
16	Parikh et al. [37]	USA	2018	2	PFS	FOLFOX6 + BEV FOLFIRI + BEV	188 188	23.9 27.5
17	Carrato et al. [38]	Spain	2017	2	ORR	FOLFOX4 + Pmab FOLFIRI + Pmab	40 40	37 41
18	Yamada et al. [39]	Japan	2018	3	PFS	FOLFOX (CapOx) + BEV S-1 + IRI + BEV	244 243	33.6 34.8
19	Nakayama et al. [40]	Japan	2018	2	ORR	CapOx + BEV CapIRI + BEV	54 53	26.7 28.7

OS overall survival, AEs adverse events, PFS progression-free survival, ORR objective response rate, NA not available, CapOx capecitabine + Ox, CapIRI capecitabine + IRI, FOLFOX and OXAFAFU 5-FU + folinic acid + Ox, FOLFIRI and IRIFAFU 5-FU + folinic acid + IRI, TEGAFOX tegafur + folinic acid + Ox, TEGAFIRI tegafur + folinic acid + IRI, BEV bevacizumab, Cmab cetuximab, Pmab panitumumab

ISSN: 1471-2407